CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
Nuklearmedizin - NuclearMedicine · 01.04.2024 · 63 (02) · 57-61
DOI: 10.1055/a-2194-9965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2024. Verfasst von Rudolf Werner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
- Clinical Department of Nuclear Medicine, University Hospital AKH Vienna, Wien, Austria.
- Institute of Experimental Cancer Research, Ulm University Hospital, Ulm, Germany.
- Department of Medicine III, School of Medicine, Technical University of Munich, Munchen, Germany.
- Department of Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany.
- Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Zitieren
APA
Werner, R., Haug, A., Buske, C., Heidegger, S., Illert, A. L., Bassermann, F., Herhaus, P., Buck, A., Duell, J., Topp, M. S., Kraus, S., Einsele, H., Lapa, C., Raderer, M., Lenz, G., Habringer, S., von Tresckow, B., & Keller, U. (2024). CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin - NuclearMedicine, 63(02), 57-61. https://doi.org/10.1055/a-2194-9965
Vancouver
Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, et al. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin - NuclearMedicine. 2024;63(02):57-61. doi:10.1055/a-2194-9965
BibTeX
@article{Werner2024,
author = {Werner, Rudolf and Haug, Alexander and Buske, Christian and Heidegger, Simon and Illert, Anna L and Bassermann, Florian and Herhaus, Peter and Buck, Andreas and Duell, Johannes and Topp, Max S and Kraus, Sabrina and Einsele, Hermann and Lapa, Constantin and Raderer, Markus and Lenz, Georg and Habringer, Stefan and von Tresckow, Bastian and Keller, Ulrich},
title = {CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2024},
volume = {63},
number = {02},
pages = {57--61},
doi = {10.1055/a-2194-9965}
}
EUVIMED